Concepts (120)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV-1 | 12 | 2012 | 163 | 1.400 |
Why?
|
| Anti-HIV Agents | 4 | 2011 | 149 | 1.190 |
Why?
|
| Antiretroviral Therapy, Highly Active | 7 | 2012 | 64 | 1.140 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 3 | 2021 | 18 | 1.000 |
Why?
|
| Autoimmune Diseases | 2 | 2021 | 241 | 0.840 |
Why?
|
| HIV Infections | 10 | 2012 | 772 | 0.840 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2021 | 371 | 0.700 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 558 | 0.590 |
Why?
|
| CD4-Positive T-Lymphocytes | 8 | 2021 | 425 | 0.510 |
Why?
|
| Virus Replication | 7 | 2012 | 319 | 0.500 |
Why?
|
| Anti-Retroviral Agents | 2 | 2012 | 30 | 0.480 |
Why?
|
| HIV | 1 | 2011 | 46 | 0.400 |
Why?
|
| HIV Protease Inhibitors | 4 | 2011 | 21 | 0.370 |
Why?
|
| Viral Load | 1 | 2010 | 150 | 0.360 |
Why?
|
| Viremia | 2 | 2008 | 55 | 0.340 |
Why?
|
| Inhibitory Concentration 50 | 4 | 2011 | 64 | 0.300 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2011 | 1961 | 0.290 |
Why?
|
| HIV Fusion Inhibitors | 3 | 2011 | 3 | 0.280 |
Why?
|
| Reverse Transcriptase Inhibitors | 4 | 2011 | 23 | 0.280 |
Why?
|
| Models, Biological | 3 | 2011 | 1749 | 0.270 |
Why?
|
| Immune Tolerance | 3 | 2021 | 337 | 0.250 |
Why?
|
| Autoimmunity | 2 | 2021 | 160 | 0.220 |
Why?
|
| Antiviral Agents | 4 | 2011 | 512 | 0.210 |
Why?
|
| Integrase Inhibitors | 3 | 2011 | 3 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2021 | 36 | 0.200 |
Why?
|
| Virus Internalization | 2 | 2010 | 39 | 0.190 |
Why?
|
| HEK293 Cells | 2 | 2021 | 615 | 0.190 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 1540 | 0.180 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 302 | 0.180 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 302 | 0.170 |
Why?
|
| Virus Latency | 2 | 2009 | 33 | 0.160 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2021 | 295 | 0.160 |
Why?
|
| Disease Susceptibility | 1 | 2017 | 193 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 3095 | 0.120 |
Why?
|
| Drug Resistance, Viral | 2 | 2011 | 51 | 0.120 |
Why?
|
| Acyclovir | 2 | 2011 | 107 | 0.120 |
Why?
|
| Humans | 17 | 2021 | 86678 | 0.110 |
Why?
|
| T-Lymphocytes | 2 | 2017 | 1195 | 0.110 |
Why?
|
| Mice | 3 | 2021 | 11356 | 0.110 |
Why?
|
| Mutation | 3 | 2021 | 3968 | 0.110 |
Why?
|
| Signal Transduction | 3 | 2021 | 3243 | 0.110 |
Why?
|
| Animals | 5 | 2021 | 26590 | 0.110 |
Why?
|
| Lymphocyte Activation | 4 | 2021 | 728 | 0.110 |
Why?
|
| Reverse Transcription | 2 | 2008 | 14 | 0.100 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2011 | 3 | 0.100 |
Why?
|
| Drug Combinations | 1 | 2012 | 224 | 0.100 |
Why?
|
| Virion | 1 | 2011 | 59 | 0.100 |
Why?
|
| Herpesviridae | 1 | 2011 | 14 | 0.100 |
Why?
|
| HIV Long-Term Survivors | 1 | 2010 | 1 | 0.100 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2010 | 143 | 0.090 |
Why?
|
| Guanine | 2 | 2009 | 208 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2010 | 118 | 0.090 |
Why?
|
| Drug Discovery | 1 | 2010 | 103 | 0.090 |
Why?
|
| Protein Engineering | 1 | 2010 | 140 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 895 | 0.090 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2009 | 14 | 0.090 |
Why?
|
| Biological Factors | 1 | 2009 | 18 | 0.090 |
Why?
|
| Virus Activation | 1 | 2009 | 41 | 0.080 |
Why?
|
| Receptors, CXCR4 | 1 | 2008 | 44 | 0.080 |
Why?
|
| Immunologic Memory | 1 | 2008 | 152 | 0.070 |
Why?
|
| Hepatitis B | 1 | 2007 | 74 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2010 | 7998 | 0.070 |
Why?
|
| Phylogeny | 2 | 2008 | 1137 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 1169 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 2706 | 0.060 |
Why?
|
| Phenotype | 1 | 2011 | 2380 | 0.060 |
Why?
|
| Thymocytes | 1 | 2021 | 30 | 0.050 |
Why?
|
| Peripheral Tolerance | 1 | 2021 | 2 | 0.050 |
Why?
|
| Clonal Anergy | 1 | 2021 | 30 | 0.050 |
Why?
|
| Thymus Gland | 1 | 2021 | 195 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2021 | 165 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 159 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 2 | 2010 | 305 | 0.040 |
Why?
|
| Catalysis | 1 | 2017 | 203 | 0.040 |
Why?
|
| Substrate Specificity | 1 | 2017 | 347 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2017 | 408 | 0.040 |
Why?
|
| Immunity | 1 | 2017 | 136 | 0.040 |
Why?
|
| Protein Transport | 1 | 2017 | 411 | 0.030 |
Why?
|
| Cell Line | 2 | 2011 | 2469 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2017 | 1106 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2017 | 1458 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 1718 | 0.020 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2010 | 3 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2010 | 94 | 0.020 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2010 | 93 | 0.020 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2010 | 94 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2010 | 165 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 376 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2010 | 268 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2011 | 315 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 596 | 0.020 |
Why?
|
| HIV Long Terminal Repeat | 1 | 2009 | 4 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 679 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2010 | 485 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 1921 | 0.020 |
Why?
|
| Gene Library | 1 | 2009 | 130 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2010 | 460 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2009 | 646 | 0.020 |
Why?
|
| Spleen | 1 | 2009 | 430 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2009 | 201 | 0.020 |
Why?
|
| Lamivudine | 1 | 2007 | 13 | 0.020 |
Why?
|
| Zidovudine | 1 | 2007 | 16 | 0.020 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2007 | 14 | 0.020 |
Why?
|
| Virulence | 1 | 2008 | 271 | 0.020 |
Why?
|
| Hepatitis B virus | 1 | 2007 | 43 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2007 | 66 | 0.020 |
Why?
|
| Cell Death | 1 | 2008 | 256 | 0.020 |
Why?
|
| Peptides | 1 | 2010 | 639 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 2062 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2010 | 1286 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2007 | 329 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 3030 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2009 | 445 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2010 | 2819 | 0.020 |
Why?
|
| Cytokines | 1 | 2008 | 778 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 1830 | 0.010 |
Why?
|
| Male | 2 | 2021 | 40988 | 0.010 |
Why?
|
| Adult | 2 | 2011 | 25659 | 0.010 |
Why?
|
| Time Factors | 1 | 2008 | 5214 | 0.010 |
Why?
|
| Middle Aged | 1 | 2007 | 25040 | 0.010 |
Why?
|